Want to join the conversation?
$ABBV 2Q15 Call: Earlier this year, we entered into collaboration with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies. We recently received an Orphan Drug Designation for HUMIRA and initiated a phase I program. We are on track to start clinical development with C2N in Alzheimer’s disease in 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.